The Board resolution dated March 17, 2022, the Board of Directors of Imexpharm Corporation approved the following issues:
Unit: billion dongs
Content
Plan in 2022
Performance in 2021
% Growth
Total net revenue & other
1,450.0
1,290.6
12.4%
Profit before tax
275.0
238.9
15.1%